Table 2.
Summary of preliminary data and comparison studies of selective serotonin reuptake inhibitors for the treatment of alcohol dependence
| Authors | Medication | Behavioral intervention | Adherence component | Provider | Medication adherence | Session attendance | Treatment completion | Follow-up completion |
| Preliminary Data (first 121 randomized participants) | ||||||||
| Anthenelli etal. (ongoing, single-site) | Citalopram | MI-CET (weekly for 5 visits, bi-weekly for 4 visits) | Yes | Clinical psychology trainees, physician, masters-level counselor | Took ≥ 80% doses: A: 79% P: 91% (MEMS caps) | A: 8.1/9 (90%) P: 8.4/9 (93%) | A: 81% P: 88% (12-wk. tx. phase) | A: 72% P: 80% (6-month post-treatment) |
| Comparison Studies | ||||||||
| Kranzler et al. (2006)a (N=328, multisite) | Sertraline | CET (weekly for 4 visits, biweekly for 3 visits) | Yes | NR | Took ≥ 80% doses: A: 74%, 76% P: 74%, 77% (riboflavin) | NR | A: 56%, 59% P: 56%, 78% (10-wk. tx. phase) | NR |
| Moak et al. (2003) (N = 82, single-site) | Sertraline | CBT (from Project MATCH, weekly for 12 weeks) | No | NR | Took ≥ 75% doses: A: 79% P: 77% (riboflavin) | A: 10.5/12 (88%) P: 10.8/12 (90%) | A: 84% P: 67% (12-wk. tx. phase) | NR |
| Pettinati et al. (2001)a (N = 100, single-site) | Sertraline | Twelve-step facilitation (weekly, 14 weeks) + self-help referral | No | Counselor, unspecified credentials | A: 73%, 76% P: 79%, 81% (riboflavin) | A: 8.1/14 (58%), 8.3/14 (59%) P: 7.6/14 (54%), 8.6/14 (61%) | A: 63%, 65% P: 48%, 56% (14-wk. tx. phase) | NR |
Notes: MI-CET = motivational interviewing and compliance enhancement therapy; A = active medication; P = placebo; MEMS = Medication Event Monitoring System; wk. = week; tx. = treatment; NR = not reported; CBT = cognitive-behavioral therapy.
a
Multiple values for treatment adherence and retention data reflect subgrouping of participants by depressive symptoms.